Safety and Efficacy of an Intrastromal Transform™ Corneal Allograft (TCA) for Presbyopia Correction
A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Intrastromal Implant of the Transform Corneal Allograft (TCA) for Providing Near Vision in Presbyopic Subjects
Sponsor: Allotex, Inc.
Terminated
COVID-19
Listed as NCT03671135, this NA trial focuses on Presbyopia and remains terminated or withdrawn. Sponsored by Allotex, Inc., it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2024 — Jul 2024 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Apr 2022 — Mar 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Active Not Recruiting NA
▶ Show 3 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Apr 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Nov 2019 [monthly]
Not Yet Recruiting NA
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allotex, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .